675 results about "First myocardial infarction" patented technology

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a myocardial infarction risk assessment method, system and equipment based on multi-modal interpretability. The method comprises the following steps: constructing a dynamic weighted fuzzy cognitive map model for myocardial infarction risk assessment; inputting the aggregated feature vector into a dynamic weighted fuzzy cognitive map model, updating the activation value of each concept node by adopting the finely-adjusted weight and the activation function until a preset condition is met to obtain a final activation value of each concept node, and taking the final activation value of the myocardial infarction risk concept node as a myocardial infarction risk assessment result; calculating the contribution degree of each physiological index in the aggregated feature vector according to a myocardial infarction risk assessment result; searching a maximum influence propagation path from each source node to the target node to obtain at least one maximum influence propagation path; and constructing an interpretable myocardial infarction risk assessment report based on the contribution degree of each physiological index and the at least one maximum influence propagation path. According to the invention, interpretable and high-precision model evaluation is realized.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The invention discloses an acute myocardial infarction diagnosis method based on interpretable hybrid ensemble learning. The specific implementation process is as follows: performing data preprocessing on collected original chest pain data; the adaptability of a single basic algorithm is enhanced through nested iterative optimization and global hyper-parameter tuning; dynamic multi-strategy integration is utilized to select an optimal integration strategy, and layered feature abstraction, probability calibration fusion and a consensus decision mechanism are included; in order to improve clinical transparency, a game theory marginal contribution analysis framework is constructed, and SHAP values of global and local feature contributions are quantified; collaboratively optimizing data-driven feature dimension reduction and clinical knowledge verification on the basis of SHAP value ranking, screening out six key clinical features, and constructing a hybrid integrated learning model; the method is further used for STEMI, NSTEMI and non-AMI diagnosis, and the complex diagnosis adaptability of the method is verified. According to the method, algorithm diversity and clinical transparency are integrated, and effective acute myocardial infarction diagnosis is realized.

The present disclosure provides compositions and methods related to the delivery of therapeutic medicines to the heart for treating a cardiac injury, such as those that occur due to a myocardial infarction (MI). In particular, the present disclosure provides novel hydrogel-based compositions that safely and effectively deliver a therapeutic agent to the pericardial cavity of the heart to treat the cardiac injury.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

A steering wheel system is disclosed for monitoring a driver's vital signs of a driver. The steering wheel system comprises a steering wheel and sensors integrated into the steering wheel. The sensors are configured to detect one or more driver vital signs. The steering wheel system comprises a memory storing computer executable instructions, and a processor configured to execute the computer executable instructions. The processor receives the one or more vital signs from the array of sensors, wherein the one or more vital signs correspond to cortisol levels, alcohol levels, one or more proteins associated with an occurrence stroke, one or more biomarkers associated with myocardial infarctions, temperature, pulse rate, and oxygen levels. The processor determines a health risk of the driver based at least in part on the vital signs and alerts the driver in response to the health risk exceeding a certain health risk level.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The embodiment of the invention provides a myocardial infarction risk prediction model training method and related equipment, and belongs to the technical field of machine learning. The myocardial infarction risk prediction model training method comprises the steps of obtaining initial training data, performing multiple times of characteristic variable screening on the initial training data through a single factor analysis method and an LASSO regression method to obtain training case data, and inputting the training case data into a BP neural network model for nonlinear data processing to obtain the prediction probability of myocardial infarction occurrence. And performing parameter optimization on the BP neural network model according to the prediction probability and the real occurrence probability to obtain a myocardial infarction risk prediction model. According to the embodiment of the invention, nonlinear processing can be carried out on high-dimensional or multivariable training case data through the BP neural network model, and the processing capability of complex data and the accuracy and stability of myocardial infarction risk prediction are improved.

The application relates to a myocardial injury risk assessment method and device, computer equipment and a storage medium. The method comprises the following steps: obtaining and analyzing a resting electrocardio signal to obtain a high-frequency QRS envelope curve and a resting low-frequency electrocardio signal; analyzing the high-frequency QRS envelope curve to obtain resting high-frequency QRS characteristics including a resting positive lead number, a resting critical lead number, a first target lead number, a second target lead number, a third target lead number and a high-frequency morphology index; the first target lead number refers to the number of leads with a wave peak number greater than or equal to a first number threshold; the second target lead number refers to the number of leads with a wave peak number equal to a second number threshold; the third target lead number refers to the number of leads with a wave peak number equal to a third number threshold; analyzing the resting low-frequency electrocardio signal to obtain old myocardial infarction information and other resting low-frequency characteristics; and analyzing a myocardial injury risk assessment characteristic set including the resting high-frequency QRS characteristics and the resting low-frequency characteristics to obtain a myocardial injury risk assessment score.

The invention discloses application of nano-iron in vascular endothelial cells, and belongs to the technical field of cell engineering and genetic engineering. According to the invention, PEI coated Fe3O4 is taken as a research object, the application of PEI coated Fe3O4 in vascular endothelial cells is researched by adopting a molecular and cell biology method, and regulation of PEI coated Fe3O4 on vascular endothelial regeneration of the vascular endothelial cells after myocardial infarction is verified from multiple levels and multiple angles. The invention can provide a new reference for the recovery of cardiac functions after myocardial infarction, and has good application value.

The invention discloses a related protein marker for assisting early diagnosis of acute myocardial infarction and application of the related protein marker, and is characterized in that the protein marker is at least one of GLRX, CA1, EIF4EBP1, MYL4, SOD1, BOLA2BOLA2B, DDT, TNNI3, GH1, ACY1, POMC, AK1, FABP3, YOD1, GLO1, RANBP1, TGM2, PLPBP, OLR1, CEACAM8, CD2AP, AAMDC and QDPR, and the invention further provides application of the related protein marker in preparation of a reagent or a kit for early diagnosis of myocardial infarction. The kit has the advantages that early-stage AMI diagnosis can be conveniently and quickly realized on the molecular level, the detection efficiency is high, the sensitivity is high, the pertinence is strong, and early-stage discovery and timely treatment of AMI patients are facilitated.

The invention discloses an acute myocardial infarction cardiovascular risk prediction method based on artificial intelligence. The method comprises the following steps: collecting clinical data of a patient and integrating the clinical data into an initial data set; performing cleaning, missing value processing and classification processing on the data initial set, and constructing a standardized feature data set; a competition risk outcome type is defined according to clinical follow-up visit data of the patient, and competition risk label data is constructed; an improved DeepHit model is established; training and cross validation are carried out by using the standardized feature data set and the competitive risk label data, and a training completion model is determined; and predicting the individual competition risk probability of the patient, and generating a risk level and an early warning prompt. According to the invention, individualized dynamic risk prediction is realized, and clinical diagnosis and treatment decision reliability is enhanced.

The invention belongs to the technical field of electrochemical luminescence detection equipment, and particularly relates to a microneedle patch for wearable electrochemical luminescence sensing equipment and application of the microneedle patch. The microneedle patch comprises a microneedle base and a microneedle array, the microneedle base is divided into a left area, a middle area and a right area through two parallel grooves; the middle area is conductive and light-transmitting, and the left and right areas are conductive and light-proof; the microneedle arrays are arranged in the three areas and are all subjected to conductive treatment; the three areas are separated by grooves and are insulated from one another and are not conductive; and the surface in each area has conductive performance, so that electric signals can be conducted. The light-emitting sensing equipment takes the microneedle patch as a real-time acquisition tool of a tissue fluid sample, detects the concentration of cTnI in the tissue fluid on line, realizes real-time monitoring of a marker cTnI of myocardial injury and acute myocardial infarction in vivo, has the characteristics of high detection sensitivity, portability, simplicity in operation, low cost and the like, and realizes online in-situ monitoring of wearable electrochemical luminescence of a patient.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention provides application of injectable hydrogel in preparation of a medicine for treating myocardial infarction. The injectable hydrogel is obtained by mixing aniline tetramer grafted gelatin, adipic dihydrazide modified hyaluronic acid and an aldehyde group-containing metal polyphenol complex. The injectable hydrogel has antioxidant activity, conductivity and angiogenesis promoting activity performance, and myocardial repair is promoted through synergistic regulation and control.

A phosphorothioate-containing RNA molecule that includes the nucleotide sequence: 5'-NCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC-3' (SEQ ID NO: 1), where N is uracil or thymine, is provided. The RNA molecule can include one or more phosphorothioate bonds between nucleic acid residues in one or more pairs (e.g., between nucleic acid residues in each pair) of consecutive nucleic acid residues within SEQ ID NO: 1. The RNA molecule and compositions thereof find use in treating muscle disorders, such as muscular dystrophy, heart conditions, such as heart failure or myocardial infarction, and / or conditions associated with inflammation and / or fibrosis.

The invention relates to the technical field of medicines, in particular to application of OpiCa1 or a nano-liposome thereof in preparation of medicines for treating and / or preventing myocardial fibrosis related diseases. The research on modeling and administration of myocardial infarction mice finds that the OpiCa1 and the nano-liposome thereof can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and have a better antagonistic effect on myocardial infarction and subsequent heart failure. Further transcriptomics analysis shows that in the process of treating the myocardial infarction of mice, the OpiCa1 and the nano-liposome thereof may participate in extracellular matrix degradation in myocardial remodeling and fibrosis pathways (such as TGF-beta signal pathways) to inhibit fibrosis and improve myocardial remodeling, and the purpose of relieving deterioration of the myocardial infarction is achieved.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Disclosed herein are antibodies and antigen binding fragments that bind to ANTXR1, and methods of using the same to treat cardiovascular disease. In some examples the disclosed antibodies and antigen binding fragments bind to the extracellular domain of ANTXR1. In further examples the antibodies or antigen binding fragments block the interaction between ANTXR1 and collagen, including type I or type VI collagens. In some aspects administration of a therapeutically effective amount of these antibodies can be used to prevent the maladaptive sequelae caused by a myocardial infarction, or other cardiovascular diseases.

The invention discloses application of a protein marker CA1 in preparation of a reagent or a kit for early diagnosis of myocardial infarction, and is characterized in that the protein marker is CA1 and a GH1 and CA1 protein combination, and also provides application of the related protein marker in preparation of the reagent or the kit for early diagnosis of myocardial infarction. The kit has the advantages that early-stage AMI diagnosis can be conveniently and quickly realized on the molecular level, the detection efficiency is high, the sensitivity is high, the pertinence is strong, and early-stage discovery and timely treatment of AMI patients are facilitated.

The invention discloses a myocardial infarction first-aid intelligent bracelet, which mainly comprises a physiological parameter detection module, an intelligent processing module, a medicine injection module, an alarm and communication module and a power supply module, and is characterized in that the biological parameter detection module is used for monitoring pulse, blood pressure and electrocardiosignals of a wearer in real time; the intelligent processing module is used for receiving data acquired by the physiological parameter detection module, comparing the data through a myocardial infarction early warning model and judging whether a myocardial infarction symptom exists or not; a micro injection needle and a medicine storage bin are arranged in the medicine injection module, and when the analysis module judges that a wearer has myocardial infarction symptoms, the injection needle is controlled to be punctured into the skin and inject first-aid medicine nitroglycerin; when the alarm and communication module detects myocardial infarction symptoms, alarm information is sent to an emergency center through sound, optical signals and wireless communication. By integrating the functions of detection, analysis, alarm and automatic nitroglycerin injection, instant intervention during myocardial infarction of a wearer is achieved, and golden rescue time is gained.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The invention relates to the technical field of medical typing decision, in particular to a myocardial infarction metabolic rhythm intelligent typing and administration decision method and system.The myocardial infarction metabolic rhythm intelligent typing and administration decision method comprises the steps that biological clock genes BMAL1 mRNA, a USP2-BCAT2 compound and branched chain amino acid BCAs are synchronously detected through a multi-index joint detection kit; a BCAs circadian rhythm curve is collected through a wearable monitoring patch integrating a sweat BCAs sensor and an electrocardiogram monitoring module; the invention relates to a random forest model myocardial infarction metabolic rhythm typing intelligent model. A multi-dimensional dynamic typing system is established by integrating BMAL1 methylation, a USP2-BCAT2 compound and BCAs rhythm fluctuation, and high-risk subtypes needing metabolic intervention are accurately distinguished; the concentration fluctuation of the BCAs is monitored in real time through the intelligent patch, and the abnormal metabolism state is pre-warned; and the administration opportunity is automatically optimized based on the individualized biological clock phase, and clinical pain points such as insufficient typing precision, abnormal early warning lag and administration time sequence mismatch are solved.

The invention provides a self-adaptive multifunctional hydrogel system for cardiac microenvironment regulation after myocardial infarction as well as a preparation method and application of the self-adaptive multifunctional hydrogel system, and belongs to the technical field of biomedical materials. The hydrogel system is hydrogel prepared by taking a micromolecular cross-linking agent, a polymer matrix and drug-loaded microspheres as raw materials. The hydrogel can realize staged response drug release in oxidative stress, inflammation and fibrosis microenvironments after myocardial infarction, has good injectability and self-healing property, and has the functions of ROS removal, nitric oxide release and the like. The invention provides a new strategy for tissue repair after myocardial infarction with multi-channel collaboration and accurate pathological response control.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.